Anavex Life Sciences Completes Clinical Conduct Of Drug-Drug Interaction, Absorption, Distribution, Metabolism And Excretion Trials Of Blarcamesine; Receives FDA Clearance For Its Investigational New Drug Application In Fragile X Syndrome; To Meet With FDA To Discuss Inclusion Of Participants In Its Phase 3 Rett Syndrome Trial
Anavex Life Sciences Corp. ("Anavex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system diseases with significant unmet medical
Anavex finished safety tests for its experimental medicine blarcamesine. The FDA approved it to test on more patients with rare brain diseases.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.